Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $200.00 at Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective increased by equities research analysts at Cantor Fitzgerald from $170.00 to $200.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 31.21% from the company’s previous close.

ASND has been the topic of several other reports. Evercore ISI increased their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 18th. UBS Group began coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price target on the stock. The Goldman Sachs Group increased their price objective on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Oppenheimer lowered their target price on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research note on Friday, November 15th. Finally, TD Cowen decreased their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $202.36.

Ascendis Pharma A/S Price Performance

ASND opened at $152.43 on Tuesday. The company has a market capitalization of $9.25 billion, a P/E ratio of -21.47 and a beta of 0.64. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00. The stock’s fifty day moving average is $134.83 and its two-hundred day moving average is $133.36.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. Equities analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several large investors have recently bought and sold shares of ASND. Point72 Asia Singapore Pte. Ltd. purchased a new position in Ascendis Pharma A/S during the 4th quarter worth approximately $28,000. Wilmington Savings Fund Society FSB acquired a new position in Ascendis Pharma A/S in the third quarter valued at $30,000. Jones Financial Companies Lllp raised its holdings in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 197 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after buying an additional 328 shares during the period. Finally, Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S during the 3rd quarter worth approximately $60,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.